BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28621166)

  • 21. Comparison of chemotherapy with or without asparaginase for extranodal nasal NK/T-cell lymphoma in children and adolescents.
    Zhen Z; Huang H; Lin T; Li Z; Zhen X; Xia Z; Zhu J; Lu S; Sun F; Wang J; Huang J; Sun X
    Pediatr Blood Cancer; 2021 May; 68(5):e28901. PubMed ID: 33484107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma study.
    Kim SJ; Kim K; Kim BS; Kim CY; Suh C; Huh J; Lee SW; Kim JS; Cho J; Lee GW; Kang KM; Eom HS; Pyo HR; Ahn YC; Ko YH; Kim WS
    J Clin Oncol; 2009 Dec; 27(35):6027-32. PubMed ID: 19884539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma.
    Qi F; Xie Y; Wang D; Chai Y; Chen B; Sun Y; Liu W; Qi S; Wei Y; Fang H; Zhao D; Gui L; Yang Y; Feng X; Ding N; Mi L; Shu S; Li Y; Song Y; Dong M; Zhu J
    Ann Hematol; 2022 Sep; 101(9):2021-2034. PubMed ID: 35798977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A clinical observation of treatment of peripheral T-cell lymphoma with L-asparaginase-containing combination chemotherapy].
    Yao G; Xie W; Zhou D; He D; He J; Shi J; Luo Y; Zheng W; Wei G; Lin M; Ye X; Cai Z; Huang H
    Zhonghua Nei Ke Za Zhi; 2015 Feb; 54(2):111-7. PubMed ID: 25907840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma: a pilot study.
    Wen JY; Li M; Li X; Chen J; Lin Q; Ma XK; Dong M; Wei L; Chen ZH; Wu XY
    Asian Pac J Cancer Prev; 2014; 15(15):6275-81. PubMed ID: 25124611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of a pegaspargase-based regimen in the treatment of newly-diagnosed extranodal natural killer/T-cell lymphoma.
    Li L; Zhang C; Zhang L; Li X; Wu JJ; Sun ZC; Fu XR; Wang XH; Chang Y; Wang R; Qiu YJ; Zhang MZ
    Neoplasma; 2014; 61(2):225-32. PubMed ID: 24299319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. L-asparaginase-based treatment of 15 western patients with extranodal NK/T-cell lymphoma and leukemia and a review of the literature.
    Jaccard A; Petit B; Girault S; Suarez F; Gressin R; Zini JM; Coiteux V; Larroche C; Devidas A; Thiéblemont C; Gaulard P; Marin B; Gachard N; Bordessoule D; Hermine O
    Ann Oncol; 2009 Jan; 20(1):110-6. PubMed ID: 18701429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical study of l-asparaginase in the treatment of extranodal NK/T-cell lymphoma, nasal type.
    Yong W
    Hematol Oncol; 2016 Jun; 34(2):61-8. PubMed ID: 25899032
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of improved overall survival with decreased distant metastasis following asparaginase-based chemotherapy and radiotherapy for intermediate- and high-risk early-stage extranodal nasal-type NK/T-cell lymphoma: a CLCG study.
    Zheng X; He X; Yang Y; Liu X; Zhang LL; Qu BL; Zhong QZ; Qian LT; Hou XR; Qiao XY; Wang H; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Xu LM; Zhang HL; Su H; Song YQ; Zhu J; Zhang YJ; Huang HQ; Wang Y; Chen F; Yin L; Qi SN; Li YX
    ESMO Open; 2021 Aug; 6(4):100206. PubMed ID: 34242966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study.
    Wei L; Wang J; Ye J; Yang L; Cong J; Li X; Wu Y; Cui X; Ding J; Yao N; Yang J
    Leuk Lymphoma; 2020 Feb; 61(2):337-343. PubMed ID: 31517553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Radiotherapy vs sequential pegaspargase, gemcitabine, cisplatin and dexamethasone and radiotherapy in newly diagnosed early natural killer/T-cell lymphoma: A randomized, controlled, open-label, multicenter study.
    Zhang L; Wang Y; Li X; Li L; Wang X; Sun Z; Wu J; Fu X; Zhang X; Yu H; Wang G; Chang Y; Yan J; Zhou Z; Wu X; Nan F; Li W; Zhang M
    Int J Cancer; 2021 Mar; 148(6):1470-1477. PubMed ID: 33034052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
    Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
    Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics, treatment, and survival of 30 patients with gastrointestinal natural killer/T-cell lymphoma.
    Liu JX; Liu X; Yang Y; Liu WP; Wang Y; He X; Zhang LL; Qu BL; Qian LT; Hou XR; Qiao XY; Wang H; Li GF; Zhu Y; Cao JZ; Wu JX; Wu T; Zhu SY; Shi M; Zhang HL; Su H; Zhang YJ; Zhu J; Qi SN; Li YX; Song YQ
    Cancer Rep (Hoboken); 2023 May; 6(5):e1800. PubMed ID: 36919649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.
    Kim SJ; Park S; Kang ES; Choi JY; Lim DH; Ko YH; Kim WS
    Ann Hematol; 2015 Jan; 94(1):71-8. PubMed ID: 25082384
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensive therapy can improve long-term survival in newly diagnosed, advanced-stage extranodal NK/T-cell lymphoma: A multi-institutional, real-world study.
    Wei YC; Qi F; Zheng BM; Zhang CG; Xie Y; Chen B; Liu WX; Liu WP; Fang H; Qi SN; Zhang D; Chai Y; Li YX; Wang WH; Song YQ; Zhu J; Dong M
    Int J Cancer; 2023 Nov; 153(9):1643-1657. PubMed ID: 37539660
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A controlling nutritional status score is an independent predictor for patients with newly diagnosed nasal-type extranodal NK/T-cell lymphoma based on asparaginase-containing regimens.
    Wu W; Ren K; Chen X; Li N; Zhou H; Jiang M; Yu Y; Zou L
    Cancer Med; 2023 Apr; 12(8):9439-9448. PubMed ID: 36866811
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase.
    Wang L; Wang H; Wang JH; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Zhang YJ
    Oncotarget; 2015 Oct; 6(30):30317-26. PubMed ID: 26210287
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined chemoradiation for the management of nasal natural killer (NK)/T-cell lymphoma: elucidating the significance of systemic chemotherapy.
    Guo Y; Lu JJ; Ma X; Wang B; Hong X; Li X; Li J
    Oral Oncol; 2008 Jan; 44(1):23-30. PubMed ID: 17306611
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of extranodal NK/T-cell lymphoma: From past to future.
    Yan Z; Yao S; Wang Z; Zhou W; Yao Z; Liu Y
    Front Immunol; 2023; 14():1088685. PubMed ID: 36825002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The optimal timing of radiotherapy in the combination treatment of limited-stage extranodal natural killer/T-cell lymphoma, nasal type: an updated meta-analysis.
    Cui Y; Yao Y; Chen M; Jiang Y; Ren Q
    Ann Hematol; 2021 Dec; 100(12):2889-2900. PubMed ID: 34708280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.